Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis
Background:With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney tr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.802686/full |
| _version_ | 1828815858580848640 |
|---|---|
| author | Zepei Feng Jinwei Zhang Weilong Tan Chunhui Wang Qiong Chen Chao Shen Haozhi Fan Yun Zhang Peng Huang Ming Yue |
| author_facet | Zepei Feng Jinwei Zhang Weilong Tan Chunhui Wang Qiong Chen Chao Shen Haozhi Fan Yun Zhang Peng Huang Ming Yue |
| author_sort | Zepei Feng |
| collection | DOAJ |
| description | Background:With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to negative recipients.MethodsMultiple databases were searched for a systematic and comprehensive up to March 2022. The primary outcomes included the percentage of sustained virological response at week 12 after the end of treatment (SVR12), adverse events (AEs; any grade), and severe adverse events (SAEs) as the endpoints. Publication bias was examined by using the funnel plots and Egger's test.ResultsIn total, 16 studies with 454 subjects were included in the study and the pooled estimate of SVR12, AEs, and SAEs rates were 100.0% (95% CI: 99.2-100.0), 1.9%(95%CI: 0.0-4.9), and 0.0% (95%CI: 0.0-1.5). Subgroup analysis showed that pooled SVR12 rates were 100.0% (95%CI: 99.6-100.0) for genotype (GT)1a and 96.3% (95%CI: 83.3-100.0) for GT2; 100.0% (95%CI: 98.9-100.0) for DAAs treatments; and 100.0% (95%CI: 98.2-100.0) for prophylaxis subgroup. Egger's tests showed that no publication bias was found in this study.ConclusionThis comprehensive analysis showed the high efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to HCV-negative recipients.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=246541. |
| first_indexed | 2024-12-12T10:52:28Z |
| format | Article |
| id | doaj.art-f963193a04754f04a3552804fb061f13 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-12T10:52:28Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-f963193a04754f04a3552804fb061f132022-12-22T00:26:44ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-05-01910.3389/fmed.2022.802686802686Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-AnalysisZepei Feng0Jinwei Zhang1Weilong Tan2Chunhui Wang3Qiong Chen4Chao Shen5Haozhi Fan6Yun Zhang7Peng Huang8Ming Yue9Department of Epidemiology and Biostatistics, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, ChinaDepartment of Anesthesiology, Affiliated Drum Tower Hospital of Medical College of Nanjing University, Nanjing, ChinaInstitute of Epidemiology and Microbiology, Eastern Theater Command Centers for Disease Prevention and Control, Nanjing, ChinaInstitute of Epidemiology and Microbiology, Eastern Theater Command Centers for Disease Prevention and Control, Nanjing, ChinaInstitute of Epidemiology and Microbiology, Eastern Theater Command Centers for Disease Prevention and Control, Nanjing, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, ChinaDepartment of Information, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaBackground:With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to negative recipients.MethodsMultiple databases were searched for a systematic and comprehensive up to March 2022. The primary outcomes included the percentage of sustained virological response at week 12 after the end of treatment (SVR12), adverse events (AEs; any grade), and severe adverse events (SAEs) as the endpoints. Publication bias was examined by using the funnel plots and Egger's test.ResultsIn total, 16 studies with 454 subjects were included in the study and the pooled estimate of SVR12, AEs, and SAEs rates were 100.0% (95% CI: 99.2-100.0), 1.9%(95%CI: 0.0-4.9), and 0.0% (95%CI: 0.0-1.5). Subgroup analysis showed that pooled SVR12 rates were 100.0% (95%CI: 99.6-100.0) for genotype (GT)1a and 96.3% (95%CI: 83.3-100.0) for GT2; 100.0% (95%CI: 98.9-100.0) for DAAs treatments; and 100.0% (95%CI: 98.2-100.0) for prophylaxis subgroup. Egger's tests showed that no publication bias was found in this study.ConclusionThis comprehensive analysis showed the high efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to HCV-negative recipients.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=246541.https://www.frontiersin.org/articles/10.3389/fmed.2022.802686/fullantiviral agentsHCV-viremiaHepatitis Ckidney donorskidney transplantmeta-analysis |
| spellingShingle | Zepei Feng Jinwei Zhang Weilong Tan Chunhui Wang Qiong Chen Chao Shen Haozhi Fan Yun Zhang Peng Huang Ming Yue Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis Frontiers in Medicine antiviral agents HCV-viremia Hepatitis C kidney donors kidney transplant meta-analysis |
| title | Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis |
| title_full | Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis |
| title_fullStr | Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis |
| title_short | Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis |
| title_sort | efficacy and safety of direct acting antivirals in kidney transplantation from hcv viremic donors to negative recipients a meta analysis |
| topic | antiviral agents HCV-viremia Hepatitis C kidney donors kidney transplant meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.802686/full |
| work_keys_str_mv | AT zepeifeng efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT jinweizhang efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT weilongtan efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT chunhuiwang efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT qiongchen efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT chaoshen efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT haozhifan efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT yunzhang efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT penghuang efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis AT mingyue efficacyandsafetyofdirectactingantiviralsinkidneytransplantationfromhcvviremicdonorstonegativerecipientsametaanalysis |